Catalyst overview
Research summary
This catalyst tracks a Phase 2b data readout for EVO756 (MRGPRX2 Antagonist) in Migraine. The expected timing is based on the latest available company guidance and may change.
03/05/26:- Planning Phase 2b migraine trial, with initiation targeted for Mid-2026. 04/06/26:- Migraine prophylaxis Phase 2b study initiation guided to Q3 2026. 05/07/26:- Ph2b migraine prophylaxis trial initiation planned for Mid-2026; topline data anticipated in 2027. 06/29/26:- Screening began in Ph2b migraine trial; patient dosing expected to start imminently. 07/30/26:- First patient dosed in Ph2b migraine trial. Top-line data expected in 2027. 08/06/26:- Ph2b migraine trial underway; top-line data expected in 2027.
Verification
Confirm timing and program details against the company announcement or filing.